KOD biotech catalysts & pipeline

KODIAK SCIENCES INC · Data as of 2026-10-25

Upcoming catalysts

Zenkuda (tarcocimab tedromer) — NDA/BLA submission

Q4 2026

• Zenkuda multi-indication biologics license application (BLA) planned for the fourth quarter of 2026 to include five positive Phase 3 studies across wAMD, diabetic retinopathy and retinal vein occlusion

Source filing

KSI-101 — Topline data

Dec 2026

Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026

Source filing

KSI-101 — NDA/BLA submission

Q2 2027

We are planning to file a BLA for KSI-101 in the second quarter of 2027.

Source filing

Explore the free biotech catalyst calendar